Table 3.
Treatment-related adverse events occurring > 10% for continuous dosing (n=15)
| Adverse Events | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|---|---|---|---|---|
| Blood/Bone Marrow | ||||
| Anemia | 1 | |||
| Neutropenia | 1 | 3 | 2 | |
| Cardiovascular | ||||
| Hypotension | 2 | 1 | ||
| Thrombosis | 2 | |||
| Constitutional symptoms | ||||
| Fatigue | 4 | 1 | ||
| Dermatology/skin | ||||
| Rash/desquamation | 4 | |||
| Pruritus | 5 | 1 | ||
| Gastrointestinal | ||||
| Constipation | 2 | 1 | ||
| Diarrhea | 4 | |||
| Flatulence | 3 | |||
| Nausea | 4 | |||
| Metabolic/Laboratory | ||||
| SGPT | 2 | |||
| Neurology | ||||
| Dizziness | 3 | 1 | ||
| Neuropathic Sensory | 4 | |||
| Pulmonary | ||||
| Pleural effusion | 2 |